文献速递系统性红斑狼疮

贝利尤单抗治疗儿童系统性红斑狼疮长期疗效与安全性的真实世界数据 meta 分析

Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该 meta 分析纳入 16 项队列研究和试验,评估贝利尤单抗在儿童系统性红斑狼疮(SLE)中的长期疗效与安全性。结果显示,加用贝利尤单抗在 6 个月时改善疾病控制与安全性,12 个月时降低复发风险;与标准免疫治疗相比,SLEDAI 评分下降更显著、不良事件更少、狼疮肾炎缓解率更高。

要点

  • 贝利尤单抗使 SLEDAI 评分 6 个月降 10.16 分、12 个月降 17.71 分。
  • 12 个月复发率 7%,6 个月和 12 个月不良事件率分别为 12% 和 46%。
  • 与标准免疫治疗比,6 个月 SLEDAI 降幅更大(MD 2.86,P<0.001)。

核心结论

  • 在儿童 SLE 中,加用贝利尤单抗可在 6 个月改善疾病控制与安全性,并在 12 个月降低复发风险。

研究设计与样本

  • 纳入 16 项队列研究和试验,检索 PubMed、Embase、Cochrane Library 和万方数据库。
  • 单臂分析采用随机效应模型,双臂比较计算风险比(RR)和均数差(MD)。

主要发现

  • SLEDAI 评分较基线 6 个月降低 10.16 分,12 个月降低 17.71 分。
  • LLDAS 达标率 6 个月为 42%,12 个月为 79%。
  • 平均糖皮质激素剂量 6 个月减少 19.88 mg/天,12 个月减少 11.84 mg/天。
  • 12 个月复发率为 7%,不良事件率 6 个月为 12%、12 个月为 46%。
  • 狼疮肾炎完全缓解率 6 个月为 88%,12 个月为 94%。

关键数值与推荐

  • 与标准免疫治疗相比,6 个月 SLEDAI 评分降幅更大(MD 2.86,P<0.001)。
  • 与标准免疫治疗相比,6 个月不良事件更少(RR 0.37,P=0.004)。
  • 与标准免疫治疗相比,6 个月狼疮肾炎缓解率更高(RR 1.26,P=0.03)。
  • 与标准免疫治疗相比,12 个月复发风险更低(RR 0.44,P=0.02)。

临床怎么用

  • 儿童 SLE 患者可在标准免疫治疗基础上加用贝利尤单抗以改善 6 个月疾病控制并减少不良事件。
  • 加用贝利尤单抗有助于降低 12 个月复发风险,并可减少糖皮质激素用量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Belimumab is the first biologic approved for children aged over 5 years with systemic lupus erythematosus (SLE); however, evidence on its long-term efficacy and safety remains limited. This meta-analysis synthesized available data to provide quantitative evidence for clinical decision-making. METHODS: PubMed, Embase, Cochrane Library and Wanfang databases were searched for studies reporting belimumab outcomes in pediatric SLE. Random-effects models were used for single-arm analyses, and risk ratios (RRs) and mean differences (MDs) were calculated for double-arm comparisons. RESULTS: Sixteen cohort studies and trials were included. Belimumab reduced the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score by 10.16 points at 6 months and 17.71 points at 12 months from baseline. LLDAS was achieved 42% at 6 months and 79% at 12 months. Mean glucocorticoid dose decreased by 19.88 mg/day at 6 months and 11.84 mg/day at 12 months. The 12-month flare rate was 7%, and adverse event (AE) rates were 12% and 46% at 6 and 12 months, respectively. In lupus nephritis (LN), complete remission occurred in 88% at 6 months and 94% at 12 months. Compared with standard immunotherapy, belimumab produced significant greater SLEDAI score reduction (MD, 2.86; P < 0.001), fewer AEs (RR, 0.37; P = 0.004) and higher LN remission rates (RR, 1.26; P = 0.03) at 6 months and lower flare risk at 12 months (RR, 0.44; P = 0.02). CONCLUSION: In pediatric SLE, add-on belimumab improves disease control and safety at 6 months and reduces flare risk at 12 months compared with standard immunotherapy. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: https://www.crd.york.ac.uk/prospero, CRD420251142943.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Le TPA, Loh EW, Tam KW, et al. Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data. Rheumatology (Oxford). 2026. PMID: 42036838. doi:10.1093/rheumatology/keag236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。